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Abstract
Background
Preoperative therapy has gained wide interest in advanced gastric cancer patients due to its
potential advantages of improved disease control. Selection of high risk patients based on
preoperative staging is crucial to choose the candidates for neoadjuvant therapy.
Methods
Our institutional review board approved this retrospective study and waived the require-
ment for patient consent. We searched 394 advanced gastric cancer patients (pT2-4)
who underwent curative resection in 2010 without neoadjuvant therapies. Two abdominal
radiologists independently reviewed the preoperative CT including tumor depth on CT
(CT-tumor depth), which was categorized as follows: intramural, minimal extramural
(<1mm), spiculated extramural(1mm) and nodular extramural infiltration. The impact of
clinicoradiologic factors on disease recurrence and disease free survival (DFS) was eval-
uated. Recursive partitioning analysis was performed to suggest prediction models for
recurrence.
Results
Of total 394 patients, 86 patients (21.8%) experienced recurrence. Spiculated (1mm) and
nodular extramural tumor infiltration and CT size of 5-10cm were independent predictors of
disease recurrence and significantly associated with worse DFS. Lymph node involvement
on CT was not significantly associated with patient outcome. Among patients with same
pT4a stage, the recurrence rate rises and DFS gets worse as the extramural tumor infiltra-
tion progresses (P < 0.001). The prediction model for recurrence revealed that size and CT-
tumor depth were the two major discriminating factors.
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Conclusion
CT-tumor depth and size could be used as independent predictors for prognosis. Preopera-
tive CT can be used for prognostic stratification to select high risk patients for whom neoad-
juvant therapies might be considered.
Introduction
Gastric cancer is the third and fifth leading worldwide cause of death in males and females,
respectively [1] and is one of the most common cancers in Korea [2]. The only curative treat-
ment for advanced gastric cancer is complete resection of tumors with negative margins (R0
resection) and D2 lymphadenectomy. However, a significant number of completely resected
patients experience tumor recurrence [3, 4]. For locally advanced gastric cancer, perioperative
chemotherapy has been established as the standard treatment to overcome high rates of recur-
rence [5, 6]. Recently, significant evidence has indicated the advantages of neoadjuvant thera-
pies in patients with gastric cancer. Early treatment of distant microscopic disease and possible
downstaging of the primary tumor which might be achieved by neoadjuvant therapies could
yield a better outcome [7–9]. Several studies have reported that high R0 resection rate and sur-
vival were achieved with neoadjuvant chemotherapy followed by curative surgery [10–12].
In gastric cancer, computed tomography (CT) is the modality of choice for preoperative
staging. To select candidates for neoadjuvant treatment, selection of high risk patients based
on preoperative staging is needed. In cases of locally advanced rectal cancer, neoadjuvant che-
moradiotherapy is selectively performed when high-risk findings for tumor recurrence (posi-
tive circumferential margin, extramural venous invasion, extramural tumor spread, etc.) are
detected on preoperative magnetic resonance imaging (MRI) [13, 14]. However, limited data
are available to stratify patients with advanced gastric cancer.
In this study, we aimed to investigate preoperative prognostic stratification based on preop-
erative CT findings in patients with advanced gastric cancer in order to select high-risk
patients who might benefit from neoadjuvant therapy.
Materials and methods
Patient selection
This retrospective study was approved by institutional review board from our tertiary institu-
tion, Severance hospital, Yonsei University College of medicine. Requirement for informed
consent was waived. After approval by the institutional review board, we retrospectively
searched a total of 452 patients with advanced gastric cancer (pT2-4) who underwent curative
surgery without neoadjuvant therapy in 2010. Patients who had double primary cancer
(n = 17), histology other than adenocarcinoma (n = 1), less than 2 years of follow-up (n = 8),
and history of previous endoscopic mucosal resection (n = 1) were excluded. Patients with
insufficient preoperative CT images with slice thickness more than 5 mm were also excluded
(n = 6). Thus, total 419 patients were analyzed. Demographic data (age and sex) were collected
using electronic medical records.
Protocol for CT
CT scans were performed with a 16- or 64-channel multidetector CT scanner (Somatom Sen-
sation 16 and Sensation 64; Siemens Medical Solutions, Forchhein, Germany and Lightspeed
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VCT, GE Medical Systems, Milwaukee, WI, USA). Images were acquired from diaphragm
level to the symphysis pubis with detector collimations of 16 x 0.75 mm or 64 x 0.6 mm. Other
scanning parameters were as follows: 160 mAs; 120 kVp; table speed, 24 mm per rotation; and
gantry rotation time, 0.5 seconds. For gastric distention, gas distention with 2 packs of
effervescent granules was introduced. All patients received 120-150ml contrast medium intra-
venously using an automatic injector at a rate of 3–4 ml/s. Images of portal phases were
obtained. Axial and coronal images were reconstructed with 3-mm-thick sections and a 3 mm
interval.
Image review
Two board-certified abdominal radiologists with more than 10 years of experience indepen-
dently reviewed preoperative CT images and arrived at a consensus in cases with discrepancy.
Both were blinded to pathologic reports and clinical outcomes. The analyzed CT imaging char-
acteristics were tumor depth, lymph node (LN) status, presence of extramural vascular inva-
sion (EMVI), tumor size, longitudinal extent, and Borrmann type. Tumor depth on CT (CT-
tumor depth) was categorized into four groups. Group 1 was tumors confined to the stomach
wall without extramural infiltration. Cases with extramural tumor infiltration were subdivided
according to the degree of infiltration as follows: Group 2, transmural involvement of the
tumor with minimal extramural infiltration less than 1 mm; group 3, transmural involvement
of the tumor with 1 mm or more spiculated extramural infiltration; and group 4, transmural
involvement of the tumor with nodular extramural infiltration (Figs 1 and 2). LN involvement
on CT (CT-LN status) was categorized into two groups, N0-1 and N2-3, based on a previous
study that reported that pN2 disease was diagnosed with a reasonably high sensitivity and
specificity by CT [15]. Lymph nodes were considered metastatic if they had a short-axis diame-
ter>8 mm. EMVI was identified as serpiginous extension of the tumor within a vascular
Fig 1. Schematic illustration showing four different groups of computed tomography (CT)-tumor depth. (A)
Group 1, tumors confined to the stomach wall without extramural tumor infiltration. (B) Group 2, transmural
involvement of the tumor with minimal extramural infiltration less than 1 mm. (C) Group 3, transmural involvement
of the tumor with 1 mm or more spiculated extramural infiltration. (D) Group 4, transmural involvement of the tumor
with nodular extramural infiltration.
https://doi.org/10.1371/journal.pone.0202207.g001
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structure. Tumor size was measured as the longest diameter on the axial or coronal plane.
Tumor size was categorized into three groups: 1) less than 5 cm, 2) 5–10 cm, and 3) more than
10 cm. Longitudinal tumor extent was determined by an imaginary line from the gastroesoph-
ageal junction to the pyloric channel. Tumors which involved more than half of this line were
classified as non-localized type and if not, those were classified as localized type. Tumors were
analyzed according to the Borrmann classification and were classified as Borrmann type 4 in
cases where infiltrative stomach cancer showed no definite ulceration or mass formation.
Pathology
Postoperative pathologic stage was determined using the seventh edition of the International
Union Against Cancer (UICC)/American Joint Committee on Cancer (AJCC) staging system.
Slides were prepared from formalin-fixed, paraffin-embedded tissue blocks for histological
examination. Hematoxylin–eosin (H–E)-stained slides of each tumor were reviewed to assess
lymphovascular invasion (LVI), defined as the presence of tumor cell clusters or individual
tumor cells within an endothelium-lined space lumen or destruction of a lymphovascular wall
by tumor cells. At our institute, histopathologic reports contain only the presence or absence
of LVI and do not specify whether it is vascular or lymphatic invasion. Therefore, we evaluated
the diagnostic performance of CT-detected EMVI using pathologic LVI as the reference stan-
dard. Histologic grade was also retrieved from the pathologic report.
Fig 2. Axial images of contrast enhanced computed tomography (CT) demonstrating four different groups of CT-tumor depth.
Group 1, 2, 3 and 4 in (A), (B), (C), and (D), respectively.
https://doi.org/10.1371/journal.pone.0202207.g002
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Data analysis
The results of CT-tumor depth, CT-LN status, and EMVI on CT were compared with those of
pT, pN staging, and pathologic LVI, respectively. The incidence of patients with pathologic
serosal exposure among each subcategory of CT-tumor depth was calculated. Patients with
pN2 or pN3 were considered to have ‘advanced nodal status.’ The incidence of patients with
advanced nodal status was calculated for each subcategory of CT-tumor depth. The recurrence
rate and DFS were evaluated according to CT-tumor depth in patients with the same pT4a
stage.
Statistical analysis
Statistical analysis was performed using SPSS 20.0.0 (SPSS, Chicago, IL) and R software (ver-
sion 3.2.2; R Development Core Team, Vienna, Austria). Weighted kappa statistics were used
to evaluate the interobserver agreement for CT-tumor depth. Cochran-Mantel-Haenszel tests
were performed to examine the linear trend between extent of CT-tumor depth and pathologic
LN status. Univariate associations of clinicoradiologic factors such as age, sex, and CT findings
with recurrence status were assessed using chi-square or Fisher’s exact test. Subsequently,
parameters with a P value less than 0.05 were included in multivariate logistic regression and
the association of each parameter with recurrence was expressed as an odds ratio (OR) with a
95% confidence interval (CI).
Disease-free survival (DFS) after surgery was estimated from the date of operation to the
date of recurrence or death using the Kaplan-Meier method and compared using the log-rank
test. The impact of clinicoradiologic factors such as age, sex, and CT findings on DFS was eval-
uated using the multivariable Cox regression model. All clinicoradiologic variables except sex
were entered into the multivariate model. Hazard radios (HR) and 95% CIs were generated.
On the basis of the results of logistic regression analysis for disease recurrence, recursive
partitioning analysis (RPA) was performed to suggest prediction models for recurrence.
Receiver operating characteristic (ROC) analysis was used to assess the discriminatory powers
of the diagnostic tree model. The areas under the curve (AUCs) for receiver operating charac-
teristic analysis were calculated.
All tests were 2-sided and P values less than 0.05 were considered statistically significant.
Results
Patient characteristics
After retrospective image analysis of enrolled 419 patients, 25 who had no identifiable stomach
cancer at preoperative CT were excluded. Characteristics of 394 patients are summarized in
Table 1. The median age of enrolled patients was 57 years (range, 23–86 years). Regarding pT
stage, pT3-4 accounted for 74.4% (n = 293), while pT2 accounted for 25.6% (n = 101) of cases.
TNM stage III patients represented 49.7% (196/394) of the total sample. Pathologic LVI was
positive in 46.4% (183/394).Among total 394 patients, 82.5% (325/394) underwent adjuvant
chemotherapy.
Preoperative CT findings compared with pathologic data
The weighted kappa value between the two radiologists showed moderate agreement (0.555)
for assessing the CT-tumor depth. The distribution of pT stage was as follows: pT2, n = 101;
pT3, n = 121; pT4a, n = 168; pT4b, n = 4 (S1 Table). The incidence of pathologic serosal expo-
sure among each subcategory of CT-tumor depth was as follows: intramural, 17.5%; minimal
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extramural (<1 mm), 44.7%; spiculated extramural (1 mm), 53.3%; and nodular extramural,
77.2% (Table 2).
Table 1. Patient characteristics of included 394 patients.
Characteristics Number %
Sex
Male 265 67.3
Female 129 32.7
Age (years), median (range) 57 (23–86)
T classificationa
T2 101 25.6
T3 121 30.7
T4a 168 42.6
T4b 4 1.0
N classificationa
N0 141 35.8
N1 74 18.8
N2 79 20.1
N3 100 25.4
TNM stagea
I IB 57 14.5
II
IIA 69 17.5
IIB 72 18.3
III
IIIA 61 15.5
IIIB 64 16.2
IIIC 71 18.0
Pathologic lymphovascular invasion
No 211 53.6
Yes 183 46.4
Histologic grade
Well/Moderate differentiation 135 34.3
Poor/signet ring cell/mucinous 259 65.7
UICC/AJCC, International Union Against Cancer/American Joint Committee on Cancer (seventh edition).
aUICC/AJCC staging system, seventh edition.
https://doi.org/10.1371/journal.pone.0202207.t001
Table 2. Incidence of patients with pathologic serosal exposure and advanced nodal status among each subcate-
gory of CT-tumor depth.
CT-tumor depth Patients with pathologic serosal exposurea
(%)
Patients with advanced nodal statusb
(%)
Intramural 17.5% (22/126) 48.4% (61/126)
Minimal extramural
(<1mm)
44.7% (34/76) 57.9% (44/76)
Spiculated extramural
(1mm)
53.3% (72/135) 72.6% (98/135)
Nodular extramural 77.2% (44/57) 87.7% (50/57)
aCases with pathologic T4a or T4b were considered to have serosal exposure.
bAdvanced nodal status means pathologic N2 or N3 status.
https://doi.org/10.1371/journal.pone.0202207.t002
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The distribution of pN stage was as follows: pN0, n = 141; pN1, n = 74; pN2, n = 79; pN3,
n = 100 (S2 Table). The sensitivity, specificity, and accuracy of CT-LN status for diagnosing
advanced nodal status (pN2 and pN3) were 35.2%, 90.7%, and 65.5%, respectively.
As CT-tumor depth progressed, the incidence of patients with advanced nodal status (pN2-
3) increased (intramural, minimal extramural (<1 mm), spiculated extramural (1 mm), and
nodular extramural: 48.4, 57.9, 72.6, and 87.72%, respectively; P value < 0.001, Table 2). The
average number of pathologic metastatic LNs also showed an increasing trend as CT-tumor
depth progressed, as follows: tumors with intramural, minimal extramural (<1 mm), spicu-
lated extramural, (1 mm) and nodular extramural infiltration showed 1.8, 3.5, 6.7, and 11.1
pathologic metastatic LNs, respectively.
The sensitivity, specificity, and accuracy of CT-detected EMVI for diagnosing pathologic
LVI were 28.4%, 81.5%, and 56.9%, respectively.
The distribution of tumor size based on CT was as follows: less than 5 cm, 66.5% (n = 262);
5–10 cm, 28.2% (n = 111); and more than 10 cm, 5.3% (n = 21). The distribution of longitudi-
nal extent of tumor was as follows: localized, 93.9% (370/394) and non-localized, 6.1% (24/
394). Thirty-three patients were considered Borrmann type 4 (8.4%).
Multivariate analysis of disease recurrence
The types of recurrence were classified as locoregional, peritoneal, or distant metastasis. Locor-
egional recurrence included a soft tissue mass at the gastric bed, upper retroperitoneal LN
enlargement, or anastomosis site recurrence. Of 394 total patients, 86 (21.8%) experienced
recurrence. Distant metastasis by hematogenous spread was the most frequent site of recur-
rence (59.3%, 51/86), followed by peritoneal recurrence (44.1%, 30/68) and locoregional recur-
rence (10.5%, 9/86). The liver was the most frequently involved site of recurrence (18.6%, 16/
86). Majority had a single site of recurrence, while 12 patients (14.0%) had multiple sites of
recurrence.
On univariate analysis, all radiologic variables were significantly associated with recurrence.
Multivariate analysis with adjustment for age and CT size revealed that spiculated (1 mm)
and nodular extramural tumor infiltration and CT size of 5–10 cm were independent predic-
tors of disease recurrence (Table 3).
Using recursive-partitioning analysis based on the classification and regression tree model,
a prediction tree model for disease recurrence was established (Fig 3). Preoperative tumor size
and CT-tumor depth were the two major discriminating factors for predicting disease recur-
rence. The sensitivity, specificity, and accuracy of this model were 51.2%, 96.1%, and 78.6%,
respectively. ROC curve analyses revealed an AUC value of 0.736.
Disease-free survival after curative surgery
The median DFS after curative surgery was 44.9 months (95% CI 42.8–47.0 months). As
shown in Fig 4, DFS was significantly worse in patients with CT findings of more advanced
CT-tumor depth, CT-LN status, CT-detected EMVI, large size, non-localized longitudinal
extent, and Borrmann type 4 (all P< 0.001).
Multivariate Cox regression model with adjustment of age and CT size revealed that spicu-
lated or nodular extramural tumor infiltration, CT size of 5–10 cm, and non-localized tumor
involvement of the stomach were significantly associated with worse DFS (Table 4).
Subgroup analysis among patients with pT4a
The recurrence rate in each category of CT-tumor depth among patients with pT4a was as fol-
lows: intramural, minimal extramural (<1 mm), spiculated extramural (1 mm), and nodular
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extramural showed rates of 13.6% (3/22), 26.5% (9/34), 34.7% (25/72), and 60.0% (24/40),
respectively. As extramural tumor infiltration became more prominent, the recurrence rate
increased with statistical significance (P< 0.001). DFS was also significantly worse in patients
Table 3. Multivariable regression analysis of disease recurrence.
Variable Univariate Multivariate
OR 95% CI P OR 95% CI P
CT-tumor depth (intramural)
Minimal extramural(<1mm) 1.96 0.79–4.87 0.146 0.62 0.64–4.1 0.309
Spiculated extramural 4.38 2.07–8.26 <0.001 2.87 1.26–6.54 0.012
Nodular extramural 11.20 4.89–25.66 <0.001 6.66 2.64–16.8 <0.001
CT-LN status (cN0-1)
cN2-3 2.97 1.76–5.08 <0.001 1.39 0.73–2.64 0.312
CT EMVI (Negative)
Positive 3.81 2.27–6.40 <0.001 1.38 0.70–2.71 0.349
CT size (<5cm)
5-10cm 1. 2.25–6.42 <0.001 2.04 1.12–3.73 0.021
>10cm 5.90 2.33–14.91 <0.001 2.7 0.99–7.36 0.052
Extent (localized)
Non-localized 4.81 2.07–11.17 <0.001 1.69 0.53–5.40 0.375
Borrmann Type 4 (No)
Yes 4.81 2.07–11.17 <0.001 1.75 0.64–4.76 0.277
OR, odds ratio; CI, confidence interval; EMVI, extramural vascular invasion.
https://doi.org/10.1371/journal.pone.0202207.t003
Fig 3. Prediction tree model for disease recurrence using recursive-partitioning analysis. Preoperative tumor size
and CT-tumor depth were the two major discriminating factors for predicting disease recurrence.
https://doi.org/10.1371/journal.pone.0202207.g003
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with more progressed extramural tumor infiltration among patients with same pT4a stage
(P< 0.001) (Fig 5).
Fig 4. Kaplan-Meyer curves for disease free survival stratified to variable radiologic parameters. DFS was significantly worse in patients with CT findings of more
advanced CT-tumor depth, CT-LN status, CT-detected EMVI, large size, non-localized longitudinal extent, and Borrmann type 4.
https://doi.org/10.1371/journal.pone.0202207.g004
Table 4. Multivariate cox regression model of disease free survival using clinicoradiologic factors.
Variable HR 95% CI P
Age (continuous) 1.02 1.00–1.03 0.086
CT-tumor depth (intramural)
Minimal extramural(<1mm) 1.59 0.66–3.8 0.298
Spiculated extramural(1mm) 2.75 1.28–5.91 0.009
Nodular extramural 5.32 2.38–11.89 <0.001
CT-LN status (cN0-1)
cN2-3 1.23 0.79–1.93 0.360
CT EMVI (Negative)
Positive 1.19 0.73–1.92 0.490
CT size (<5cm)
5-10cm 1.81 1.08–3.03 0.025
>10cm 1.67 0.7–3.97 0.248
Extent (localized)
Non-localized 2.00 1.00–4.00 0.0498
Borrmann Type 4 (No)
Yes 1.32 0.69–2.52 0.409
HR, hazard ratio; CI, confidence interval; EMVI, extramural vascular invasion.
https://doi.org/10.1371/journal.pone.0202207.t004
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Discussion
As neoadjuvant chemotherapy has emerged as an attractive treatment option in patients with
advanced gastric cancer, CT staging prior to treatment has become more important for pre-
dicting prognosis. Traditionally, pathologic stage is the most important prognostic factor in
gastric cancer. However, pathologic stage can only be determined after resection and preoper-
ative treatment could alter the baseline pathologic stage. Effective and accurate preoperative
staging is required in the era of preoperative therapy for resectable gastric cancer.
A large-scale retrospective study suggested that preoperative CT staging is an independent
predictor of long-term survival and it should be regarded as a stratification factor in a random-
ized clinical trial of preoperative therapy in patients with gastric cancer [8]. However, their
prognostic model was based on a study population including a considerable proportion of
patients with lower clinical T stage (mucosa and submucosa). These early gastric cancer
patients were excluded from the current study because they do not require neoadjuvant treat-
ment. By selecting only advanced gastric cancer patients, the potential targets for neoadjuvant
therapy became our study subjects and we aimed to identify patients who might benefit from
neoadjuvant therapy.
The current seventh edition of the UICC/AJCC system separates tumors with extramural
fat infiltration into T3 (subserosa invasion) and T4a (serosal exposure). This makes CT based
T classification more challenging, because T3 and T4a lesions have similar CT findings (extra-
mural soft tissue infiltration), and their differentiation is very difficult due to limitations of CT
spatial resolution. For these reasons, we divided tumors as those with or without extramural
infiltration. Tumors with extramural fat infiltration were classified into three subcategories
according to the degree of extramural fat infiltration (minimal extramural (<1 mm), spicu-
lated extramural (1 mm), and nodular extramural), instead of cT staging, which corresponds
to pathological T staging. Our results demonstrated that tumors with more advanced extramu-
ral infiltration showed higher rates of pathologic serosal exposure. Also, tumors with spicu-
lated (1 mm) and nodular extramural infiltration on CT indicate higher risk of recurrence
and worse DFS compared to tumors with lesser extramural infiltration. Similar results have
occurred in patients with the same pT4a stage, indicating that even among patients sharing the
same pathologic T stage, prognosis can differ based on preoperative extramural tumor depth.
The worse prognosis of tumors with spiculated (1 mm) or nodular extramural infiltration
might be explained by higher rates of pathologic serosal exposure. In addition, more frequent
LN involvement and a larger number of metastatic LNs have been observed in tumors with
advanced extramural infiltration. This contributes to their worse prognosis because lymph
Fig 5. Subgroup analysis among patients with pT4a stage. As extramural tumor infiltration progressed, recurrence rate
significantly increased (A) and the disease free survival became worse (B).
https://doi.org/10.1371/journal.pone.0202207.g005
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node involvement is the most important factor for overall survival in patients with gastric can-
cer following curative resection and the survival rates markedly decrease with an increase in
the number of metastatic lymph nodes [16, 17]. Therefore, we believe that our CT-tumor
depth could be more easily assessed than T classification and might be used to stratify high-
risk patients who might benefit from neoadjuvant therapies.
Pathologic N stage is one of the most reliable prognostic indicators for patients with resect-
able gastric cancer [17, 18]. However, accurate preoperative N staging by CT is limited because
differentiation of small LNs with micrometastasis and large reactive LNs is difficult based on
size criteria [8]. In our study, we categorized preoperative LN status into two groups (N0-1 vs.
N2-3) based on a previous report that contrast-enhanced CT offers reasonably high sensitivity
and specificity forpN2 [15]. However, LN status on preoperative CT was significantly associ-
ated with disease recurrence and DFS only on univariate analysis, but not on multivariate anal-
ysis. This result could be attributed to inaccurate preoperative N staging by CT.
Pathological studies show that vascular invasion of gastrointestinal cancer allows tumor
cells to embolize through the portal circulation, resulting in distant metastases through hema-
togenous spread [19]. MRI-detected EMVI in patients with rectal cancer is an established inde-
pendent significant risk factor for poor prognosis and is used to select patients for neoadjuvant
therapies [14, 19]. A previous pathological study demonstrated that EMVI was an independent
pathologic feature for subsequent visceral metastases and worse disease-specific survival in
patients with esophageal and gastric cancer [20, 21]. Recently, there was a study which assessed
the clinical significance of preoperative CT-detected EMVI. Although the study provided a rel-
atively short follow up period and small sample size, it suggested that CT-detected EMVI-posi-
tive patients had significantly lower 1-year progression free survival (PFS) than EMVI-
negative patients, in addition, EMVI was also an independent prognostic factor in stage III
gastric cancer [22]. According to our study, the CT-detected EMVI-positive group had a sig-
nificantly worse 5-year DFS than the CT-detected EMVI-negative group. CT-detected EMVI
showed a significant association with disease recurrence and DFS by univariate analysis,
although it was not an independent factor by multivariate analysis. Thus, CT-detected EMVI
might be used as a prognostic factor to stratify patients as high-risk who could undergo neoad-
juvant therapy followed by surgery, as MRI-detected EMVI is used in rectal cancer. Until now,
limited studies have addressed the clinical significance of CT-detected EMVI, and further
studies are required for validation.
Tumors of 5–10 cm had significantly worse prognosis than tumors<5 cm. Tumors larger
than 10 cm showed high odds ratio and hazard ratio for disease recurrence and DFS, respec-
tively, but without statistical significance. This might be attributed to the small number of
tumors larger than 10 cm (n = 21). Still, our study suggests that CT size is an independent
prognostic factor and one of the major discriminators of the prognosis prediction model. A
previously mentioned large retrospective study showed that tumor size 4.5 cm was signifi-
cantly associated with worse overall survival in patients who underwent curative gastrectomy
[8]. Tumor size was also one of the independent risk factors for disease recurrence among
patients with T1-2 and lymph node-negative stomach cancer in the United States and China
[23]. Additionally, macroscopic tumor size (7 cm) was one of the most important risk factors
for peritoneal recurrence in patients with advanced stomach cancer who underwent adjuvant
chemotherapy after D2 gastrectomy [24]. These results implicate large tumor size as a risk fac-
tor for poor prognosis in patients with stomach cancer.
Our study has some limitations. First, this is a retrospective study. Inclusion of patients
with tumor stage pT2-4 who did not undergo neoadjuvant therapy might have led to selection
bias. Second, preoperative staging was based on CT alone, which is not the best modality for
staging T classification and peritoneal carcinomatosis. Although we assessed CT-tumor depth
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instead of classical cT staging for better characterization, we did not consider endoscopic ultra-
sound (EUS) findings, which provide better resolution compared to CT. Thus, preoperative
staging using EUS might be used for validating our preoperative staging using CT-tumor
depth. However, despite the favorable performance of EUS in staging, the influence of EUS on
patient management remains controversial. EUS seems to have a greater impact on manage-
ment of early stages rather than in advanced stages, thus, its role has been more emphasized in
patients with early gastric cancer [25]. In addition, EUS is not routinely performed in all
patients with advanced gastric cancer while CT, which is the modality of choice for preopera-
tive staging, is more feasible and available in majority of patients. Thus, we believe that preop-
erative staging using CT itself without EUS conveys significance for assessing the tumor
characterization.
In conclusion, as neoadjuvant therapies in patients with advanced gastric cancer have
gained wide interest, clinical staging prior to preoperative treatment has become more impor-
tant for predicting prognosis. CT-tumor depth and CT size could be used as independent pre-
dictors for prognosis. Tumors with extramural infiltration more than 1 mm showed
significantly higher disease recurrence and worse DFS. CT can be used for prognostic stratifi-
cation to select high risk patients for whom neoadjuvant therapies might be considered.
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